← All organizations

Eyenovia Inc.

For profit

Also known as: EYENOVIA | Eyenovia Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

Last known activity

Mar 4, 2024

Timeline

2010s

Jun 1, 2014
Eyenovia Inc.— Founded

2020s

May 5, 2023
phenylephrine— NDA Secondary Org

Drugs by trial phase (5 distinct, 8 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (2 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

latanoprost

Indications

Studied for

Marketed drugs (2)

Recent trials (14)

NCT05114486Study chairPhase 3Nov 3, 2021
NCT05114486Lead sponsorPhase 3Nov 3, 2021
NCT04907474Study directorPhase 4May 24, 2021
NCT04907474Lead sponsorPhase 4May 24, 2021
NCT04657172Study chairPhase 3Dec 31, 2020
NCT04657172Lead sponsorPhase 3Dec 31, 2020
NCT03942419Study directorPhase 3Jun 3, 2019
NCT03942419Lead sponsorPhase 3Jun 3, 2019
NCT03751098Lead sponsorPhase 3Dec 1, 2018
NCT03751098Study directorPhase 3Dec 1, 2018
NCT03751631Study directorPhase 3Nov 15, 2018
NCT03751631Lead sponsorPhase 3Nov 15, 2018
NCT03480906Lead sponsorN/AMar 12, 2018
NCT02946125Lead sponsorPhase 2Oct 1, 2016

Details

Founded: New York, NY, US Jun 1, 2014
Last known activity: Mar 4, 2024